Condensed Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating activities
Net loss	$ (15,698,139)	$ (9,819,746)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	473,799	365,100
Accretion of discount on NuvoGen obligation	229,232	141,551
Bad debt expense (recovery), net	44,854	117,467
Provision for excess inventory	273,752
Amortization of deferred financing costs	37,461	2,700
Amortization of discount on term loan	120,627	16,125
Amortization of final payment premium on term loan	116,398
Loss on settlement of convertible notes	705,217
Amortization of discount on convertible notes	90,222
Share-based compensation expense	223,787	119,506
Change in redeemable convertible preferred stock warrant liability	239,683	56,323
Loss on disposal of assets	67,780	35,960
Changes in operating assets and liabilities:
Accounts receivable	59,444	(353,117)
Inventory	(854,120)	(547,457)
Prepaid expenses and other	(505,918)	1,123
Accounts payable	(254,423)	(347,323)
Accrued liabilities	(47,367)	60,925
Deferred revenue	(8,532)	(64,548)
Other long term liabilities		(7,617)
Net cash used in operating activities	(14,686,243)	(10,223,028)
Investing activities
Purchase of property and equipment	(950,278)	(605,931)
Purchase of available-for-sale securities	(36,473,957)
Net cash used in investing activities	(37,424,235)	(605,931)
Financing activities
Proceeds from exercise of stock options	34,048	21,305
Draws on line of credit		750,000
Payments on line of credit		(750,000)
Payments on NuvoGen obligation	0	(1,206,250)
Proceeds from exercise of E warrants	8,948
Deferred offering costs	(1,002,930)	(193,280)
Deferred financing costs	(75,523)
Payments on equipment lease	(21,933)	(21,932)
Proceeds from term loan		10,680,000
Proceeds from issuance of convertible note warrants	1,354
Settlement of fractional common shares	(2,925)
Proceeds from convertible notes	4,500,000
Proceeds from initial public offering	47,654,190
Net cash provided by financing activities	51,095,229	16,708,150
(Decrease) increase in cash and cash equivalents	(1,015,249)	5,879,191
Cash and cash equivalents at beginning of period	3,613,392	1,815,289
Cash and cash equivalents at end of period	2,598,143	7,694,480
Noncash investing and financing activities
Accretion of preferred stock issuance costs	35,046	71,175
Accretion of Series D and E redeemable convertible preferred stock dividends	1,165,932	2,405,987
Deferred offering costs reclassified to distributions in excess of capital	2,297,079
Accrual of deferred offering and finance costs		657,499
Allocation of Series E warrant convertible notes debt discount	741,828	301,507
Conversion of convertible notes and related accrued interest to common stock	4,544,384
Fixed asset purchases payable at period end	272,847
Reclassification of convertible preferred stock liability warrants to equity warrants	1,616,140
Supplemental cash flow information
Cash paid for interest	701,250	145,367
Series B
Noncash investing and financing activities
Adjustment to Series B book value		112,903
Common Stock
Noncash investing and financing activities
Conversion of convertible preferred stock to common stock	57,356,049
Series D and Series E Warrants
Noncash investing and financing activities
Net exercise of Series D and Series E warrants	95,914
Series E Warrants
Noncash investing and financing activities
Accretion of Series E warrant discount	127,616	251,893
Series E Preferred Stock
Financing activities
Proceeds from sale of preferred stock, net of issuance costs		$ 7,428,307
Noncash investing and financing activities
Net exercise of Series D and Series E warrants	$ 11,312